Cell Therapy for Parkinson's Disease

Overview

Journal Cell Transplant

Specialties Cell Biology
General Surgery

Date 2017 Nov 9

PMID 29113472

Citations 41

Authors

Takao Yasuhara

Masahiro Kameda

Tatsuya Sasaki

Naoki Tajiri

Isao Date

Affiliations

Soon will be listed here.

Abstract

Cell therapy for Parkinson's disease (PD) began in 1979 with the transplantation of fetal rat dopamine-containing neurons that improved motor abnormalities in the PD rat model with good survival of grafts and axonal outgrowth. Thirty years have passed since the 2 clinical trials using cell transplantation for PD patients were first reported. Recently, cell therapy is expected to develop as a realistic treatment option for PD patients owing to the advancement of biotechnology represented by pluripotent stem cells. Medication using levodopa, surgery including deep brain stimulation, and rehabilitation have all been established as current therapeutic strategies. Strong therapeutic effects have been demonstrated by these treatment methods, but they have been unable to stop the progression of the disease. Fortunately, cell therapy might be a key for true neurorestoration. This review article describes the historical development of cell therapy for PD, the current status of cell therapy, and the future direction of this treatment method.

Citing Articles

The therapeutic use of clonal neural stem cells in experimental Parkinson´s disease.

Nelke A, Garcia-Lopez S, Caso J, Pereira M Stem Cell Res Ther. 2024; 15(1):356.

PMID: 39385216 PMC: 11465761. DOI: 10.1186/s13287-024-03965-0.

Application of Pro-angiogenic Biomaterials in Myocardial Infarction.

Liang T, Liu J, Liu F, Su X, Li X, Zeng J ACS Omega. 2024; 9(36):37505-37529.

PMID: 39281944 PMC: 11391569. DOI: 10.1021/acsomega.4c04682.

Therapeutic role of neural stem cells in neurological diseases.

Yang L, Liu S, Liu Y, Zhu F, Xiong M, Hu D Front Bioeng Biotechnol. 2024; 12:1329712.

PMID: 38515621 PMC: 10955145. DOI: 10.3389/fbioe.2024.1329712.

Possible role of lncRNAs in amelioration of Parkinson's disease symptoms by transplantation of dopaminergic cells.

Amini A, Esmaeili F, Golpich M NPJ Parkinsons Dis. 2024; 10(1):56.

PMID: 38472261 PMC: 10933336. DOI: 10.1038/s41531-024-00661-x.

Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling.

Beghini D, Kasai-Brunswick T, Henriques-Pons A Int J Mol Sci. 2024; 25(4).

PMID: 38397069 PMC: 10889263. DOI: 10.3390/ijms25042392.

References

Barker R, Parmar M, Kirkeby A, Bjorklund A, Thompson L, Brundin P . Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?. J Parkinsons Dis. 2016; 6(1):57-63. PMC: 4927930. DOI: 10.3233/JPD-160798. View

Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T . Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2007; 26(1):101-6. DOI: 10.1038/nbt1374. View

Lige L, Zengmin T . Transplantation of Neural Precursor Cells in the Treatment of Parkinson Disease: An Efficacy and Safety Analysis. Turk Neurosurg. 2016; 26(3):378-83. DOI: 10.5137/1019-5149.JTN.10747-14.4. View

Sasaki T, Liu K, Agari T, Yasuhara T, Morimoto J, Okazaki M . Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease. Exp Neurol. 2015; 275 Pt 1:220-31. DOI: 10.1016/j.expneurol.2015.11.003. View

Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y . Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest. 2005; 115(1):102-9. PMC: 539189. DOI: 10.1172/JCI21137. View

Kawasaki H, Mizuseki K, Nishikawa S, Kaneko S, Kuwana Y, Nakanishi S . Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron. 2000; 28(1):31-40. DOI: 10.1016/s0896-6273(00)00083-0. View

Toledo-Aral J, Mendez-Ferrer S, Pardal R, Echevarria M, Lopez-Barneo J . Trophic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body-grafted parkinsonian rats. J Neurosci. 2003; 23(1):141-8. PMC: 6742142. View

Gibson S, Gao G, McDonagh K, Shen S . Progress on stem cell research towards the treatment of Parkinson's disease. Stem Cell Res Ther. 2012; 3(2):11. PMC: 3392771. DOI: 10.1186/scrt102. View

Chambers S, Fasano C, Papapetrou E, Tomishima M, Sadelain M, Studer L . Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009; 27(3):275-80. PMC: 2756723. DOI: 10.1038/nbt.1529. View

10.

Okano H, Yamanaka S . iPS cell technologies: significance and applications to CNS regeneration and disease. Mol Brain. 2014; 7:22. PMC: 3977688. DOI: 10.1186/1756-6606-7-22. View

11.

Date I, Ohmoto T . Neural transplantation and trophic factors in Parkinson's disease: special reference to chromaffin cell grafting, NGF support from pretransected peripheral nerve, and encapsulated dopamine-secreting cell grafting. Exp Neurol. 1996; 137(2):333-44. DOI: 10.1006/exnr.1996.0034. View

12.

Xia N, Zhang P, Fang F, Wang Z, Rothstein M, Angulo B . Transcriptional comparison of human induced and primary midbrain dopaminergic neurons. Sci Rep. 2016; 6:20270. PMC: 4740755. DOI: 10.1038/srep20270. View

13.

Yasuhara T, Matsukawa N, Hara K, Yu G, Xu L, Maki M . Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. J Neurosci. 2006; 26(48):12497-511. PMC: 6674904. DOI: 10.1523/JNEUROSCI.3719-06.2006. View

14.

Hallett P, Deleidi M, Astradsson A, Smith G, Cooper O, Osborn T . Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell. 2015; 16(3):269-74. PMC: 4462124. DOI: 10.1016/j.stem.2015.01.018. View

15.

Carlsson T, Carta M, Munoz A, Mattsson B, Winkler C, Kirik D . Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain. 2008; 132(Pt 2):319-35. DOI: 10.1093/brain/awn305. View

16.

Date I, Asari S, Ohmoto T . Two-year follow-up study of a patient with Parkinson's disease and severe motor fluctuations treated by co-grafts of adrenal medulla and peripheral nerve into bilateral caudate nuclei: case report. Neurosurgery. 1995; 37(3):515-8; discussion 518-9. DOI: 10.1227/00006123-199509000-00022. View

17.

Kim J, Sebastiano V, Wu G, Arauzo-Bravo M, Sasse P, Gentile L . Oct4-induced pluripotency in adult neural stem cells. Cell. 2009; 136(3):411-9. DOI: 10.1016/j.cell.2009.01.023. View

18.

Wakamori T, Agari T, Yasuhara T, Kameda M, Kondo A, Shinko A . Cognitive functions in Parkinson's disease: relation to disease severity and hallucination. Parkinsonism Relat Disord. 2014; 20(4):415-20. DOI: 10.1016/j.parkreldis.2014.01.002. View

19.

Lindvall O, Rehncrona S, Gustavii B, Brundin P, ASTEDT B, Widner H . Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet. 1988; 2(8626-8627):1483-4. DOI: 10.1016/s0140-6736(88)90950-6. View

20.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View